{'fraction_non_alphanumeric': 0.046875, 'fraction_numerical': 0.034254807692307696, 'mean_word_length': 5.0989010989010985, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A Prospective Multi-Center Registry of Patients Hospitalized for Non- ST Segment Elevation Acute Coronary Syndrome in High Complexity Centers. In-hospital and 6-month Outcomes (Buenos Aires I)

Background: Non-ST elevation acute coronary syndrome (NSTE-ACS) management has evolved over the past years, based on newpharmacological agents and progress in revascularization techniques. The aim of this study was to analyze the current managementof NSTE-ACS in high complexity centers of the city of Buenos Aires and the province of Buenos Aires.Methods: Patients hospitalized in 21 centers with coronary care unit, 24-hour catheterization lab availability and cardiovascularsurgery were prospectively enrolled in the study and followed up for 6 months after hospital discharge.Results: The registry included 1,100 consecutive patients: 61% corresponded to non-ST-segment elevation myocardial infarction and37.4% were unstable angina. Mean age was 65.4 ± 11.5 years and 77.2% were men; 27.6% had diabetes mellitus and 31.5% previousmyocardial infarction. An early invasive management was used in 86.7% of cases with a median time to coronary angiography of 18hours (IQR 7-27.7). During hospitalization, 5.2% of the patients presented reinfarction, 0.3% stroke and overall mortality was 2.7%.The rate of bleeding events ≥ BARC type 2 was 10.1%. At 6-month follow-up, the rates of reinfarction, ACS and overall mortalitywere 8.4%, 10.9% and 5.7%, respectively.Conclusions: The registry demonstrated a predominantly invasive therapeutic approach in patients with NSTE-ACS treated in highcomplexity centers with low rates of in-hospital complications and during follow-up.